SUMMARY Acycloguanosine, a recently developed compound with high inhibitory activity against viruses belonging to the herpes group, has been evaluated in experimental herpes simplex keratitis in rabbits in comparison with trifluorothymidine and preparations of idoxuridine and vidarabine at present in clinical use. All compounds were used in the form of ophthalmic ointments which were applied 5 times a day at intervals of 2 hours. Treatment began on the third day of infection and was continued for 4 days. Complete cure was obtained with acycloguanosine and idoxuridine; trifluorothymidine and vidarabine were considerably less effective. Acycloguanosine was equally effective when given intravenously in the form of its sodium salt, and could be detected in the tear fluid in inhibitory concentrations when given by mouth. The compound was relatively free from toxicity.
The use of specific antiviral agents is an established form of treatment for herpes simplex keratitis, but in many cases treatment is ineffective or gives rise to hypersensitivity and toxic manifestations. These have been summarised by McGill et al. (1976) . Treatment with idoxuridine may cause contact dermatitis, punctate epithelial keratopathy, follicular conjunctivitis, and thickening of the lid margins associated with stenosis or occlusion of the punctum. Trifluorothymidine may cause contact dermatitis, punctate epithelial keratopathy, and oedema of the corneal epithelium. The same signs of toxicity have been observed with vidarabine, and there is a further report that trifluorothymidine may cause filamentary keratosis (Coster et al., 1976) . These drugs also have the disadvantage of not being effective by systemic routes of administration.
The present paper describes a new compound, acycloguanosine, having a number of favourable properties which may make it a useful addition to the range of drugs at present available for the treatment of herpes simplex keratitis. Acycloguanosine [9-(2-hydroxyethoxymethyl)-guanine] is an acyclic nucleoside possessing high inhibitory activity against certain viruses of the herpes group, including herpes simplex and varicellazoster. Its antiviral activity and general properties have been described by Schaeffer et al. (1978) , and are summarised in Tables 1 and 2 , which include comparative data for 3 other compounds used in the treatment of herpes simplex keratitis. General properties and some aspects of the clinical pharmacology of the compounds are compared in Table 2 . Low solubility is a disadvantage except in the case of trifluorothymidine, but acycloguanosine forms a sodium salt with an aqueous solubility of 2% which is suitable for intravenous injection. It is catabolised only to the extent of less than 5%, so that practically all the compound is present as the active form. It is present in the blood and urine after oral administration in laboratory animals and human volunteers, and can be found in the tear fluid after intravenous and oral administration of the sodium salt. One hour after oral administration to a dog in a dose of 25 mg/kg acycloguanosine was present in the aqueous in a concentration 20 times greater than the 100% inhibitory concentration as established with type 1 herpes simplex virus in tissue culture .
These generally favourable properties make acycloguanosine a suitable candidate for clinical trial, and as a preliminary its antiviral effect was evaluated in rabbits infected on the cornea with herpes simplex virus, and the results are described in the present work as a comparative study with trifluorothymidine and commercially available ophthalmic preparations of idoxuridine and vidarabine. Also described are the results of preclinical toxicity tests in which the ocular safety of acycloguanosine was evaluated in several species of animals treated topically and by parenteral routes of administration.
Materials and methods

EXPERIMENTAL HERPES SIMPLEX KERATITIS
Ophthalmic preparations
In initial experiments acycloguanosine was administered as aqueous suspensions in concentrations ranging from 0-25 to 1 %. Benzalkonium chloride -was added in a concentration of 0-01 % as a preservative. Subsequently, a series of ointments was prepared in soft paraffin ophthalmic base, in which the concentration of acycloguanosine ranged from 0-03 to 3%. These formulations were prepared in the Wellcome Pharmaceutical Research and Development Laboratories, Greenville, NC, USA.
Idoxuridine was tested in the form of Kerecid, a 0-5 % ophthalmic ointment marketed by Smith, Kline and French Laboratories, Welwyn Garden City, Herts, England.
Vidarabine (ara-A) was used in the form of Vira-A, a 3 % ophthalmic ointment marketed by Parke, Davis & Co., Ann Arbor, Michigan, USA.
Intravenous preparation
Ampoules containing 500 mg of acycloguanosine in the form of the freeze-dried sodium salt were supplied by the Wellcome Pharmaceutical Research and Development Laboratories, Greenville, NC, USA. The material was re-dissolved by the addition of 25 ml of sterile distilled water. A fresh ampoule was reconstituted for each series of injections.
Animals
The experiments were carried out on New Zealand white and half-lop rabbits weighing about 2 25 kg. They were obtained from Ranch Rabbits, Crawley Down, Sussex, England. The half-lop rabbits were used in experiments requiring repeated intravenous injections.
Virus
The work was carried out with the PH8 strain of type 1 herpes simplex virus, which was obtained from Mr J. McGill, Southampton Eye Hospital, Southampton, England. The virus was grown in cultures of VERO cells. At the height of infection the cultures were disrupted by sonication. The stock suspension of virus thus obtained was placed in ampoules in volumes of 1 ml and stored at -70°C. For the infection of rabbits an ampoule was thawed and diluted to a concentration of virus of around 106 plaque-forming units per millilitre. The same stock of virus was used for all the experiments described.
Method of infection Both eyes of a rabbit were infected by a modification of the method of Jones et al. (1968) (Herrmann, 1961) Examination of the eye The eyes of all animals were evaluated by indirect ophthalmoscopy, biomicroscopy, and histological examination except where otherwise indicated. Before examination the pupils were dilated with 1 % tropicamide solution (1 % Mydriacyl, Alcon Laboratories Inc., Fort Worth, Texas, USA). In eye irritancy studies the cornea was stained with fluorescein (Fluor-I-strip, Ayerst Laboratories Inc., New York, NY, USA). At the end of the test period the animals were killed and the eyes were removed and fixed in Zenker's acetic acid solution, and processed essentially in accordance with the methods described by Levy et al. (1965) . Full anteroposterior sections approximately 7 ,um thick were taken through the optic nerve head, stained with haematoxylin-eosin, and examined by conventional light microscopy.
STUDIES
Eye irritancy study in rabbits Groups of 8 rabbits were treated with 1, 3, and 6 % ointments of acycloguanosine in white petrolatum vehicle. Control groups were dosed with vehicle or balanced saline. The test materials were instilled into the conjunctival sac of 1 eye of each rabbit 5 times daily at 90-minute intervals for 21 consecutive days. The untreated eye served as an additional control. The condition of the eyes was assessed numerically by the method of Draize (1959) The opportunity was taken to obtain additional data on ocular toxicity in animals used for the teratology studies described below. Teratology study in rabbits Groups of 16 to 18 pregnant rabbits were treated from the 6th to the 18th days of gestation inclusive with the same dose levels used in the rat study. The eyes were examined before treatment and on the 29th day of gestation. The animals in the control and highest dosage groups were killed on the 29th day and the eyes were examined histologically. In a repetition of the study carried out for the purpose of increasing the number of litters available for examination observations of the eyes were limited to visual examination.
Results
Teratology study in rats Groups of 21 to 25 pregnant rats were given acycloguanosine subcutaneously in doses of 6, 12-5, and 25 mg/kg twice daily from the 6th to the 15th days of gestation inclusive. Controls were given 0-9 % sodium chloride solution. The eyes of 8 rats in the control and highest dosage groups and 11 each from the other 2 dosage groups were examined before and
ACYCLOGUANOSINE EYE DROPS
In preliminary experiments to evaluate antiviral activity aqueous suspensions of acycloguanosine were tested in 10 rabbits. Cure was not always obtained with the 0 25 and 0 5% suspensions over the 4-day period of treatment, but a satisfactory effect was obtained with the 1 % suspension. The results of such an experiment are shown in Fig. 1 , 
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which illustrates the correspondence between the extent of the corneal lesions and the graphs of the Corwin scores. Healing is complete by the day after the termination of treatment and the score has fallen to zero, whereas in the control eye the ulceration has involved the greater part of the cornea and the score is still increasing.
ACYCLOGUANOSINE OPHTHALMIC OINTMENTS
In a similar dose-ranging study ophthalmic ointments containing acycloguanosine in concentrations ranging from 0-03 to 3 0% were tested in a total of 60 rabbits, 10 rabbits being used for each preparation. The mean Corwin scores for each group of 10 are shown in Fig. 2 . The 0-03 % ointment had a perceptible effect in retarding the course of infection. This inhibitory effect increased with rising concentration, and with the 1 % preparation cure was practically complete by the 4th day of treatment. The 2 and 3 % ointments were both somewhat more effective, giving the maximum curative effect with the treatment regimen employed.
COMPARISON OF ACYCLOGUANOSINE WITH KERECID, VIRA-A, AND TRIFLUOROTHYMIDINE
In similar experiments Kerecid and Vira-A were each tested in 10 rabbits and trifluorothymidine in 8. The graphs of mean Corwin scores for each preparation are included in Fig. 2 . From this it will be seen that cure by the 4th day of treatment was obtained only with acycloguanosine and Kerecid. Treatment with trifluorothymidine prevented the further extension of the ulceration, but the lesions were considerably slower in clearing up. Vira-A was less effective still.
ACYCLOGUANOSINE SODIUM SALT
In an investigation of the antiviral effect of acycloguanosine when administered by the intravenous route in the form of its sodium salt 6 rabbits were infected with type 1 herpes simplex virus in the usual way. Three were treated with the sodium salt by the schedule given in the Methods section, and the other 3 were left untreated as controls. The individual Corwin scores of the 6 rabbits are shown in Fig. 3 . Each point represents the mean score for the 2 eyes of 1 animal. Arrest of the infection is evident on the 2nd day of treatment. After the end of treatment on the 7th day of infection a few punctate areas staining with fluorescein could still be observed. The treated animals were therefore kept for another 3 days and re-examined. The corneas were completely healed with no sign of relapse of the infection. The animals were kept for 12 months and examined at weekly intervals. No evidence of recurrence was observed.
DETERMINATION OF LEVELS OF ACYCLOGUANOSINE IN THE TEAR FLUID
The levels of acycloguanosine in the tear fluid of a rabbit after a single intravenous dose of 100 mg/kg are shown in Table 3 . The level at 60 minutes is 100 times the 100% inhibitory concentration as determined by the plaque reduction method in VERO cells. Although the dose was higher than that used in the therapeutic experiment, the cure obtained with intravenous injections of 50 mg/kg may be assumed to be due to the presence of acycloguanosine in the tear fluid.
Intravenous injection was selected for the purpose of confirming that herpes simplex keratitis could be treated successfully by a systemic route. A more practical route in clinical practice would be administration by mouth. A rabbit was therefore given 100 mg/kg of the sodium salt of acycloguanosine by mouth, and the levels in the tear fluid were determined at intervals up to 240 minutes after administration. The results are given in Table 3 . It will be seen that effective levels were present at 30 minutes, and acycloguanosine was still present at 40 times the 100% inhibitory concentration after 4 hours.
TOXICITY OF ACYCLOGUANOSINE FOR THE EYE ON TOPICAL ADMINISTRATION
In the eye irritancy study no signs of irritation occurred in rabbits treated with balanced saline. Rabbits treated with the vehicle and the ointment preparations had minimal signs of irritation which were limited to the conjunctiva and seen only during The possibility of systemic treatment, high intrinsic activity, and lack of toxicity to the eye suggest that acycloguanosine should be of value in the treatment of herpes simplex keratitis in man.
